Monopar Therapeutics (MNPR) EBIT (2017 - 2026)
Monopar Therapeutics (MNPR) posted EBIT of -$4.1 million for Q3 2025, down 26.55% sequentially from -$3.2 million in Q2 2025, and down 159.89% YoY from $6.8 million in Q3 2024.
Monopar Therapeutics (MNPR) EBIT (2017 - 2026) Analysis & Trends
Monopar Therapeutics has reported EBIT for 9 years, with the latest figure at -$4.1 million in Q3 2025.
- Quarterly EBIT fell 159.89% year-over-year to -$4.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$12.1 million (down 69.49% YoY) and the FY2025 annual result came in at $8.5 million, up 258.12% from the prior year.
- EBIT retreated to -$4.1 million in Q3 2025 per MNPR's latest filing, from -$3.2 million in the prior quarter.
- Over five years, EBIT peaked at -$1.6 million in Q3 2024 and troughed at -$4.1 million in Q3 2025.
- A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT jumped 31.75% in 2024, then plunged 159.89% in 2025.
- Over 5 years, EBIT stood at -$2.7 million in 2021, then fell by 8.5% to -$2.9 million in 2022, then grew by 28.98% to -$2.1 million in 2023, then grew by 23.77% to -$1.6 million in 2024, then slumped by 159.89% to -$4.1 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$4.1 million, -$3.2 million, and -$3.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -6.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.64 Mn |
| Sep 30, 2025 | -4.09 Mn |
| Jun 30, 2025 | -3.23 Mn |
| Mar 31, 2025 | -3.22 Mn |
| Sep 30, 2024 | -1.57 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | -1.72 Mn |
| Sep 30, 2023 | -2.07 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -2.91 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.76 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -2.26 Mn |
| Sep 30, 2020 | -1.65 Mn |